Prospera Financial Services Inc purchased a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,272 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.

Other large investors also recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in Revance Therapeutics by 22.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 30,313 shares of the biopharmaceutical company’s stock valued at $591,000 after purchasing an additional 5,598 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in Revance Therapeutics during the 1st quarter valued at approximately $3,902,000. Assenagon Asset Management S.A. boosted its stake in Revance Therapeutics by 2.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 122,259 shares of the biopharmaceutical company’s stock valued at $2,384,000 after purchasing an additional 3,395 shares during the period. Inspire Investing LLC bought a new stake in Revance Therapeutics during the 1st quarter valued at approximately $238,000. Finally, Virginia Retirement Systems ET AL bought a new stake in Revance Therapeutics during the 1st quarter valued at approximately $433,000. Institutional investors own 79.94% of the company’s stock.

Revance Therapeutics Price Performance

Shares of NASDAQ:RVNC opened at $19.65 on Friday. The business has a 50 day moving average price of $14.61 and a 200 day moving average price of $15.34. Revance Therapeutics, Inc. has a twelve month low of $11.27 and a twelve month high of $30.00. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -4.86 and a beta of 1.03. The company has a quick ratio of 3.87, a current ratio of 4.01 and a debt-to-equity ratio of 14.80.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.03). Revance Therapeutics had a negative return on equity of 273.73% and a negative net margin of 305.27%. The firm had revenue of $25.26 million during the quarter, compared to the consensus estimate of $23.55 million. Research analysts predict that Revance Therapeutics, Inc. will post -3.97 earnings per share for the current year.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Articles

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating).

Receive News & Ratings for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.